International Symposium on ALS/MND w/ Prof. Jackie Hunter

Join BenevolentAI’s Board Director, Jackie Hunter, for a talk on our AI-augmented search for disease-modifying treatments for ALS

The complex aetiology and heterogeneity of neurodegenerative diseases, such as ALS, has proved a formidable barrier to the translation of basic research into effective treatments. With a rapidly ageing global population, the need to address this unmet medical need becomes ever more pressing. The exponential increase in biomedical data generation and research output, however, offers confidence that we are on the cusp of making substantial progress. This presentation will examine how the application of this technology is helping to enhance the mechanistic understanding of human disease, therapeutic target identification and uncover more effective disease-modifying treatments for ALS and other neurodegenerative diseases.

Register here →

Jackie Hunter

Board Director of BenevolentAI

Jackie Hunter is a Board Director of BenevolentAI. Jackie has over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. She founded OI Pharma Partners in 2010 to support the life science sector in harnessing the power of open innovation and most recently was Chief Executive of the Biotechnology and Biological Sciences Research Council. She holds personal chairs from St George’s Hospital Medical School and Imperial College and serves on numerous Advisory Bodies and Boards including the Technology Advisory Board of BP plc and A*Star Board Singapore. She also Chairs the Boards of Brainomix Ltd, Stevenage Bioscience Catalyst and the Sainsbury Laboratories Norwich

More Posts

You Might Also Like

BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
Notifications of persons discharging managerial responsabilities
May 5, 2022
PDMR Notification (Dr. Olivier Brandicourt)
May 5, 2022
PDMR Notification (Jean Raby)
May 5, 2022
Notifications of Major Holdings
Apr 29, 2022